As molecularly guided treatment has been increasingly used to combat the heterogeneous tumour microenvironment of CCA, targeted therapies, such as ivosidenib for patients with IDH1 mutations and pemigatinib for patients harbouring FGFR2 fusions, respectively, have been approved for use in CCA [19,20]. This evidence concerns the gene IDH1 and neoplasm.